Hims & Hers stock falls 10% on revenue miss

In this articleHIMS your favorite stocksCREATE FREE ACCOUNTThe Hers app arranged on a smartphone in New York on Feb. 12, 2025.Gabby Jones | Bloomberg | Getty Imagess of Hims & Hers Health fell 9% in ext trading on Monday after the telehealth company reported second-quarter results that missed Wall Street's expectations for revenue.Here's how the company did based on average analysts' estimates compiled by LSEG:Earnings per : 17 cents adjusted vs. 15 cents expectedRevenue: $544.8 million vs. $552 million expectedRevenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release

Hims & Hers reported a net income of $42.5 million, or 17 cents per , compared to $13.3 million, or 6 cents per , during the same period a year earlier.For its third quarter, Hims & Hers said it expected to report revenue between $570 million and $590 million, while analysts were expecting $583 million

The company said its adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA, for the quarter will be between the range of $60 million and $70 million

But it still faces eroding AI chip market Ethereum turns 10: From scrappy experiment to Wall Street's invisible backboneGoogle has dropped more than 50 DEI-related organizations from one of its funding listsAmazon stock sinks after earnings: Here are the key takeawaysHims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapved versions of the blockbuster diabetes and weight loss drugs

Compounded drugs can be mass-duced when brand-name treatments are in shortage, but the U.S

Food and Drug Administration announced in February that supply issues had been resolved.Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications

It's legal for patients to access personalized doses of the knockoffs in unique cases, such as if they are allergic to an ingredient in a branded duct, for instance

Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable

The drugmaker said Hims & Hers "failed to adhere to the law which hibits mass sales of compounded drugs" under the "false guise" of personalization.Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount.Hims & Hers will host its quarterly call with investors at 5 p.m

ET.Don’t miss these insights from CNBC Bank of America says these five stocks have more room to run ahead of earningsThese overbought stocks could take a dip after the market's record gainsGoldman Sachs is getting worried the economyWhat the prediction are saying the big Wall Street events aheadStock Chart IconStock chart iconYTD chart of Hims & Hers Health.— CNBC's Annika Kim Constantino contributed to this report.